ASLAN Pharmaceuticals Limited

Equities

ASLN

US04522R2004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
0.47 ^USD	+0.21%		-4.28%	-9.98%

Apr. 23	Technology Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading	MT
Apr. 22	Asian Equities Traded in the US as American Depositary Receipts Open Week Higher	MT

ASLAN Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 01, 2023 at 10:30 am EDT

ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the first quarter ended March 31, 2023, and provided an update on recent corporate activities.

Contact:

Tel: +65 6817 9598

Email: contact@aslanpharma.com

Latest news about ASLAN Pharmaceuticals Limited

Technology Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading	Apr. 23	MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Higher	Apr. 22	MT
ASLAN Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients	Apr. 22	CI
Asian Equities Traded in the US as American Depositary Receipts Fall Again in Friday Trading	Apr. 19	MT
Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	Apr. 18	MT
Asian Equities Traded in the US as American Depositary Receipts Remain Flat in Wednesday Trading	Apr. 17	MT
Financial, Telecoms Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Tuesday	Apr. 16	MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	Apr. 15	MT
Asian Equities Traded in the US as American Depositary Receipts Fall in Friday Trading	Apr. 12	MT
ASLAN Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 12	CI
ASLAN Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 12	CI
Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	Apr. 11	MT
Tech, Auto Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading	Apr. 09	MT
Asian Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading, End Week Lower	Apr. 05	MT
Asian Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	Apr. 02	MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	Apr. 01	MT
Asian Equities Traded in the US as American Depositary Receipts Nudge Lower in Thursday Trading	Mar. 28	MT
Asian Equities Traded in the US as American Depositary Receipts Flat in Tuesday Trading	Mar. 26	MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading	Mar. 25	MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Lower in Friday Trading	Mar. 22	MT
Asian Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Mar. 21	MT
Asian Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading	Mar. 20	MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	Mar. 19	MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Sharply Higher in Monday Trading	Mar. 18	MT
HC Wainwright Cuts ASLAN Pharmaceuticals Price Target to $9 From $17, Maintains Buy Rating	Mar. 18	MT

Chart ASLAN Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company's portfolio is led by eblasakimab (ASLAN004), a potential human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. It is conducting a Phase II b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis (AD). The Company is also developing farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a therapy for autoimmune disease. The Company is also focused on developing antagonists of the aryl hydrocarbon receptor (AhR), an immune checkpoint inhibitor, through a joint venture.

Sector

Biotechnology & Medical Research

Calendar

2024-04-24 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.47 USD

Average target price

9.5 USD

Spread / Average Target

+1,921.28%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ASLAN PHARMACEUTICALS LIMITED	-9.98%	10.63M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.31%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-8.40%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs